Medical Advisor GI Oncology at @AstraZeneca. Prior Oncologist at AOU #Novara, @UniAvogadro. PhD @UniGenova. Prior #ESMO Fellow at @CNIO_Cancer Madrid
Milan, Lombardy
Joined January 2019
- Tweets195
- Following240
- Followers261
- Likes222
Carlo Cattrini 🇮🇹 retweeted
1/9 Glad to announce that the #CAPTURE study manuscript has been published today in @Annals_Oncology
Would you like to learn more about it? Just follow this #tweetorial thread 👇
annalsofoncology.org/article…
Carlo Cattrini 🇮🇹 retweeted
They analyzed data from 4 multicentre observational studies including 729 patients with a prevalence of 13.2% (96 patients) for BRCA mutations
annalsofoncology.org/article…
@Dav_Lorente
@dalameda
@CCattrini
2/2
Just out in @Annals_Oncology the CAPTURE study. Big prospective collection #mCRPC patients to study #BRCA. Thanks to @Dolmos77 & @Ecastromarcos for including @UniAvogadro and AOU Novara in this fantastic study. annalsofoncology.org/article…
Carlo Cattrini 🇮🇹 retweeted
Enfortumab vedotin & Pembrolizumab improving PFS & OS by 55% & 53% respectively compared to platinum based chemo in 1st line UC (+avelumab in 30%). Chemo has not been beaten before (despite multiple efforts). RR and CR of 68% & 29% is hard to beat. DOR not reached (1/3)#ESMO2023
We are going to collect clinical data and surgery samples of patients with testicular cancer and #Down Syndrome for the #TETRIS study #IGG-06. If you are interested, complete this survey 👉
forms.gle/9Q82ck1AMYK2L8D98
If you are a patient write to: [email protected]
Very proud to see my PhD project at @UniGenova published in @SciReports. Thanks to @ALEDIGNUS12 for support at @UniAvogadro. Time to investigate the role of #ceramides in #mCRPC.
Link 👉 rdcu.be/doT5L
Carlo Cattrini 🇮🇹 retweeted
Combination of Parpi and ARSI is a hot and controversial topic. Here our meta-analysis on 3 phaseIII trial sciencedirect.com/science/ar… @gbanna74 @carlomessina15 @CCattrini @RebuzziSara @biostat84 @GFornarini @AkashManiam @MatteoBauckneht @AlastairGreyst2 @plummer_ruth @OingC1
Carlo Cattrini 🇮🇹 retweeted
Another important research about the Real-World treatment for metastatic renal cell carcinoma by international ARON Group
Thanks to my friend Matteo Santoni for this our collaboration
@TargetedOnc
Carlo Cattrini 🇮🇹 retweeted
We are seeking a motivated bioinformatics / Computational Scientist to work in NGS analysis in a multidisciplinary enviroment at Hosp. Univ. 12 de Octubre Research Institute: acortar.link/7KfhhA , see recent examples of our work meetings.asco.org/abstracts-… If interested send DM
Carlo Cattrini 🇮🇹 retweeted
Don’t miss poster of the @ASCO merit award recipient @DSoldatoMD on the prognostic role of #BMI within 5 GIM and MIG RCTs! @matteolambe @delmastro_lucia @BlondeauxEva
Great honor to have contributed to these impressive results of #CAPTURE study. Save the date of #ASCO23 oral presentation! Many tks to @Dolmos77 and @Ecastromarcos
Abs#5003 @ASCO #ASCO23: Presence of somatic/germline homologous recombination repair mutations and outcomes in mCRPC #prostatecancer pts receiving first‑line Rx stratified by BRCA status. ➡️ @Dolmos77 @Dav_Lorente @Ecastromarcos @BerUrologia et al. 👉BRCA pts had significantly ⬇️rPFS, PFS2, and OS than total non-BRCA population and significantly ⬇️ PFS2 and OS than non-BRCA HRR+ pts. 👉tinyurl.com/w98k5k5c @OncoAlert @urotoday @PCFnews @Uromigos
A special thank to @Dolmos77 for his participation to #YoungOncoGU23 in Verbania. Great presentation from a great leader!
Carlo Cattrini 🇮🇹 retweeted
ARPI+PARPi benefit:
BRCAmut mCRPC>>HRRmut mCRPC >> All commers >> HRR Non-mutant mCRPC NBeije @Silke_Gillessen @AdamSharpMedOnc @EAntonarakis @morr316 @ChrisSweens1 @fizazi_karim @Ecastromarcos @quimmateo @sartor_oliver wabida rdewitt mhussain & jdebono
authors.elsevier.com/c/1gyAk…
Carlo Cattrini 🇮🇹 retweeted
📢The first patient has been enrolled in the PErioperative PEmbrolizumab - PE-PE trial (NCT05578664), for patients with olimets #mRCC eligible for surgery and/or RT. A new challenge with more than 30 centres involved in Italy 🇮🇹!
Carlo Cattrini 🇮🇹 retweeted
2 RCT have shown benefit from the addition of PARPi to ARPi in 1L mCRPC, rPFS benefit in BRCA>HRRm>all commers>HRR-. How this is going to translate in OS benefit? If as expected all commers benefit is driven by BRCA, Could we justify a more toxicity without clear OS in HRR- #GU23
Exciting participation to #prostateoftheart2023. Incredible international speakers and new insights to update our practice in #prostate cancer.
- stop ADT alone for mHSPC
- docetaxel can fit all mHSPC pts except for low-volume metachronous disease
- intensify treatment ASAP
Carlo Cattrini 🇮🇹 retweeted
#PSMA PET/CT may be predictive of treatment response in patients with mCRPC, regardless of ongoing systemic therapy. Response assessed by #PETCT is a potentially more significant prognostic factor than PSA for PFS. ow.ly/bIwj50Muquz
#NuclearMedicine @stefanofanti4
Carlo Cattrini 🇮🇹 retweeted
Delighted that NHS Scotland has now approved abiraterone for high risk M0 prostate cancer. @NHSEngland @NICEComms its urgently time to re-assess this. Big OS and MFS gains with 2y therapy
healthcareimprovementscotlan…
Carlo Cattrini 🇮🇹 retweeted
L’Oncologia @UniAvogadro assume!
In cerca di giovani oncologi con aspirazioni clinico-accademiche per unirsi al team! @ALEDIGNUS12
regione.piemonte.it/governo/…